28th Annual New Treatments in Chronic Liver Disease
Venue: Hilton La Jolla Torrey Pines
|Event Date/Time: Mar 22, 2013 / 12:30 pm - (PST)||End Date/Time: Mar 24, 2013 / 12:00 pm - (PST)|
Main Conference Overview
This CME conference will review new medications and therapies that are available, or will
soon be available, and discuss their comparative values. The results of trials using new drugs
to treat chronic viral hepatitis B and C, non-alcoholic fatty liver diseases, cholangiocarcinoma,
primary biliary cirrhosis, primary sclerosing cholangitis, hepatocellular carcinoma and
complications of end-stage liver disease will be reviewed in detail. New Treatments in Chronic
Liver Disease is a comprehensive yet concise program for updating physicians on these and
other commonly encountered problems in the treatment of liver diseases.
There was a fundamental change in the treatment of chronic hepatitis C in 2012 with the
addition of direct-acting antiviral (DAAs) drugs to current standard of care. There will be two
separate lectures devoted to this topic this year. The first will be on triple therapies which were
approved in 2011. The second will be on future therapies using two or more DAA’s, with or
We anticipate that there will be a number of new demands placed on treatment providers,
including: different pretreatment predictors, viral resistance monitoring, rash and anemia
management, and learning different therapeutic regimens. Looking beyond 2013, we see
numerous combinations of DAA’s in development including protease inhibitors, nucleoside polymerase
inhibitors, non-nucleoside polymerase inhibitors and N55A inhibitors. All of these agents
are entering phase 3 development rapidly. In hepatitis B, the treatments have not changed but
there are more mature data available on resistance, long-term HBsAg loss and clinical outcomes.
The explosive growth of NASH in the US has created a significant need for effective drug
therapy. New therapies for NAFLD and NASH are in development and will be explored. The
diagnosis and treatment of hepatocellular carcinoma will be updated as this disease is one of the
few cancers with a growing incidence in the US. New oral therapy is moving this field forward.
There will be an update on management of hepatic encephalopathy, hyponatremia and the
management of pulmonary complications in the transplant candidate.
We will review the virology, genotypes, modes of infection of HCV and characteristics of the clinical illness caused by acute and chronic infections. Tests for HCV, including PCR assays and genotyping, interpretations and indications for liver biopsies and complications of cirrhosis will all be discussed. We will show how to initiate and monitor patients during treatment with telaprevir and boceprevir, manage of side effects of rash and hematologic complications of therapy and deal with various patient populations including African Americans, HIV-coinfected and ESLD patients. Lastly, new drugs in development including protease inhibitors, nucleoside and non-nucleoside polymerase inhibitors, NS5A inhibitors, and other novel agents will be discussed.